Combination Therapy and Key Points in Patient Education
ByDanielle Roman, PharmD, BCOP, Jodi Taraba, PharmD, MS, BCOP,Heather Moore, BCOP, CPP, PharmD, Rose DiMarco, PharmD, BCPS, BCOP Panelists discuss how they are excited about future CDK4/6 inhibitor data including oral SERDs to replace fulvestrant injections, triplet combinations with newer agents, expansion into HER2-positive settings, and the potential role of ctDNA monitoring, while emphasizing key patient education points such as explaining mechanism of action differences from chemotherapy, managing expectations about common adverse effects, setting parameters for when to contact the care team, and providing resources like ChemoCare while also educating health care teams through primary literature and electronic health record care plans.